The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Abstract
The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs. Tumor cells from eight patients with clinically drug-refractory disease were evaluated by immuno-histochemical staining for monoclonal immunoglobulin (Ig) expression, nuclear proliferation antigen, P-glycoprotein (P-gly) expression, and other cellular antigens. P-gly was detected on tumor cells from six of eight patients with drug-resistant disease. Of the six patients with P-gly-positive tumors, five patients had advanced multiple myeloma and one had a drug-refractory non-Hodgkin's lymphoma. Cellular RNA analysis confirmed the over-expression of P-gly. In an effort to overcome drug resistance, a pilot study evaluated possible verapamil enhancement of chemotherapy in these eight patients. All patients had developed progressive disease while receiving a regimen containing vincristine and doxorubicin, and seven of eight patients had previously received continuous infusion vincristine and doxorubicin plus oral dexamethasone (VAD). At the time of progressive disease, continuous infusion verapamil was added to the VAD regimen. Three of the eight patients who were refractory to vincristine and doxorubicin alone responded when verapamil was added to VAD. The three patients who responded had P-gly-positive tumors. Verapamil increased the intracellular accumulation of doxorubicin and vincristine in vitro for both a P-gly-positive myeloma cell line and tumor cells from two patients with end-stage myeloma which over-expressed P-gly. The dose-limiting side effect associated with the addition of verapamil to chemotherapy was temporary impairment of cardiac function, manifest as hypotension and cardiac arrhythmia. We conclude that P-gly expression occurs in drug-refractory B-cell neoplasms and may contribute to the development of clinical drug resistance. However, other factors, such as the proliferative activity of the tumor, may also play a role in determining response to chemotherapy. The administration of verapamil along with VAD chemotherapy may partially circumvent drug resistance in patients whose tumors over-express P-gly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,887
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
Kartner, N., Evernden-Porelle, D., Bradley, G., & Ling, V. (1985) · Nature · doi:10.1038/316820a0 · Cited by 908
Multiple-Drug Resistance in Human Cancer
Flier, J. S., Underhill, L. H., Pastan, I., & Gottesman, M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162207 · Cited by 692
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.
Roninson, I. B., Chin, J. E., Choi, K. G., Gros, P., Housman, D. E., Fojo, A., Shen, D. W., Gottesman, M. M., & Pastan, I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4538 · Cited by 686
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
Barlogie, B., Smith, L., & Alexanian, R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405243102104 · Cited by 641
Cornwell, M. M., Pastan, I., & Gottesman, M. M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61633-3 · Cited by 530
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
Ozols, R. F., Cunnion, R. E., Klecker, R. W., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., & Young, R. C. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.641 · Cited by 426
Cited by
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937
Chaudhary, P. M., & Roninson, I. B. (1991) · Cell · doi:10.1016/0092-8674(91)90141-k · Cited by 934
Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., Von Hoff, D. D., et al. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7160 · Cited by 714
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy
Tishler, D. M., Weinberg, K. I., Hinton, D. R., Barbaro, N., Annett, G. M., & Raffel, C. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01657.x · Cited by 527
Multidrug resistance: molecular mechanisms and clinical relevance
Ling, V. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051053 · Cited by 522
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma
Chan, H. S. L., Haddad, G., Thorner, P. S., DeBoer, G., Lin, Y. P., Ondrusek, N., Yeger, H., & Ling, V. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252304 · Cited by 441
Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome
Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332103 · Cited by 399
Marie, J., Zittoun, R., & Sikic, B. (1991) · Blood · doi:10.1182/blood.v78.3.586.586 · Cited by 394
Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. J., & Salmon, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.1.17 · Cited by 384
Self-citationel Rouby, S., Thomas, A., Costin, D., Rosenberg, C., Potmesil, M., Silber, R., & Newcomb, E. (1993) · Blood · doi:10.1182/blood.v82.11.3452.3452 · Cited by 374
Cisternino, S., Mercier, C., Bourasset, F., Roux, F., & Scherrmann, J.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2033 · Cited by 329
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
Rowinsky, E. K., & Donehower, R. C. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90086-2 · Cited by 321
P-Glycoproteins and Multidrug Resistance
Bellamy, W. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001113 · Cited by 319
Multidrug Resistance Reversal Agents
Robert, J., & Jarry, C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030183a · Cited by 292
Farrell, R. J., Murphy, A., Long, A., Donnelly, S., Cherikuri, A., O'Toole, D., Mahmud, N., Keeling, P. W. N., Weir, D. G., & Kelleher, D. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70210-1 · Cited by 291
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Sikic, B. I. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051055 · Cited by 277
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., & Dalton, W. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1652 · Cited by 274
Self-citationAscorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells
Grad, J. M., Bahlis, N. J., Reis, I., Oshiro, M. M., Dalton, W. S., & Boise, L. H. (2001) · Blood · doi:10.1182/blood.v98.3.805 · Cited by 271
Self-citationMayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., & Schinkel, A. H. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119784 · Cited by 269
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702807 · Cited by 258
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Yanagishita, M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50119-3 · Cited by 51
MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease
Ban, J.-J., Chung, J.-Y., Lee, M., Im, W., & Kim, M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.040 · Cited by 36
Metadata
- Authors
- Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G., Taylor, C. W., Miller, T. P., & Salmon, S. E.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-04
- Volume
- 7
- Issue
- 4
- Pages
- 415-424
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1754065147
- Cited by
- 556
- References
- 29
- FWCI
- 28.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.